The company introduces its proven Mobile Fleet Predictive Maintenance solution to Australia, completing its full-suite offering for mining reliability.

SYDNEY, Oct. 20, 2025 /PRNewswire/ — Razor Labs (TASE: RZR), a global leader in AI-driven predictive maintenance for the mining industry, today announced the Australian introduction of its Mobile Fleet Predictive Maintenance solution, part of its flagship DataMind AI™ platform. The launch will take place at the International Mining and Resources Conference (IMARC) 2025, where Razor Labs is a Lead Sponsor.

Following successful deployments across major mining operations in South America and Africa, the Mobile Fleet solution extends predictive maintenance from fixed assets to include haul trucks, loaders, and excavators. It provides early fault detection, root-cause diagnosis, and operator-behavior insights that go beyond OEM systems. Together with Razor Labs’ established Fixed Asset and Visual AI offerings, it delivers a comprehensive predictive maintenance ecosystem that helps mines improve uptime, extend component life, and strengthen safety performance.

“IMARC brings together the people shaping the future of mining, and we’re proud to be part of that conversation,” said Raz Roditti, CEO and Co-Founder of Razor Labs. “After seeing strong results with our Mobile Fleet Predictive Maintenance solution in South America and Africa, we’re excited to introduce it to Australia – helping sites move from uncertainty to predictability with measurable gains in reliability, efficiency, and safety.”

DataMind AI™ uses advanced AI Sensor Fusion to integrate signals from sensors, control systems, and visual feeds into one unified reliability platform. The result is actionable insights delivered weeks before failures occur – enabling maintenance teams to make proactive, data-driven decisions that reduce downtime and maintenance costs.

Razor Labs will showcase live demonstrations of its full AI predictive maintenance suite – spanning Fixed Assets, Mobile Fleets, and Visual AI – at Booth #T15 during IMARC 2025.

Razor Labs Leadership Sessions at IMARC 2025

• Michael Zolotov, Co-Founder & CTO – Keynote: “From Data to Action – Real-World Examples of AI-Driven Predictive Maintenance in Mining”
   Hatch Mining Innovation Theatre, Tuesday, 21 October, 16:00
• Tomer Srulevich, Chief Business Officer – Panel: “How Collaboration, Technology, and Innovation are Accelerating Decarbonisation and Productivity”
   Newmont Plenary Theatre, Wednesday, 22 October, 10:45
• Liel Anisenkoo, Director of Marketing – Interview: “Digital Transformation in Mining Operations – Change Management Lessons and Case Studies”
   Mining Innovation Theatre, Wednesday, 22 October, 15:50

About Razor Labs

Razor Labs (TASE: RZR) is a global leader in AI-driven predictive maintenance for the mining industry. Operating across Australia, South Africa, the United States, and Colombia, Razor Labs helps critical industries improve asset reliability, efficiency, and safety through advanced AI Sensor Fusion and real-time diagnostics.

Website: www.razor-labs.com
LinkedIn: Razor Technologies Inc

Media Contact: Ms. Liel Anisenko, Director of Marketing | info@razor-labs.com | +61488860440

HONG KONG, Oct. 19, 2025 /PRNewswire/ — On October 19, 2025, Akeso (9926.HK) announced the final analysis results from the COMPASSION-15/AK104-302 study at the 2025 European Society of Medical Oncology Congress (ESMO 2025) .  COMPASSION-15 is a Phase III clinical trial evaluating cadonilimab, Akeso’s first-in-class PD-1/CTLA-4 bispecific antibody, in combination with oxaliplatin and capecitabine as first-line treatment for unresectable, locally advanced, recurrent, or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.  Professor Shen Lin, principal investigator from Peking University Cancer Hospital, presented the findings in an oral session at ESMO 2025.

In this final analysis presented at ESMO 2025 (median follow-up: 33.9 months), the cadonilimab regimen demonstrated enhanced long-term survival benefits in first-line advanced G/GEJ adenocarcinoma. With the extended follow-up period and more mature data, the cadonilimab treatment regimen showed a further reduction in the risk of death compared to the control group. This consistent benefit was observed across all PD-L1 expression subgroups.

The interim analysis of COMPASSION-15, with a median follow-up of 18.7 months, was previously published in Nature Medicine in January 2025. The data presented at ESMO 2025 were analyzed using the same statistical methodology.

COMPASSION-15 2025 ESMO Data

In the intent-to-treat (ITT) population:

• With long-term follow-up, the cadonilimab regimen demonstrated a significant 39% reduction in the risk of death (OS HR 0.61) versus the control group, showing further improvement over the data from the median 18.7-month follow-up (OS HR 0.66).
• With extended follow-up, in the PD-L1 CPS ≥5 population, the cadonilimab regimen demonstrated a significant 51% reduction in the risk of death (OS HR 0.49; p < 0.001) compared to the control group, showing further improvement over the data from the median 18.7-month follow-up (OS HR 0.58).
• With long-term follow-up, in the PD-L1 CPS <5 population, the cadonilimab regimen showed a significant 24% reduction in the risk of death (OS HR 0.76; 95% CI: 0.59-0.99; p = 0.019) versus the control group, with a strengthening trend of benefit compared to the data from the median 18.7-month follow-up (OS HR 0.75; 95% CI: 0.56-1.00).
• Following extended the follow-up period, the cadonilimab combination regimen maintained a favorable safety profile, with no new safety signals emerging.

In the COMPASSION-15 study, patients with PD-L1 CPS <5 (low expression) and CPS <1 (negative expression) are 49.8% and 23%, respectively, of the ITT population. This represents a higher proportion of PD-L1 low and negative patient population in COMPASSION-15 compared to previous Phase III trials of other immune checkpoint inhibitors used in the treatment of first-line gastric cancer. Previous studies have shown limited responses to PD-1/L1 inhibitors in PD-L1 low-expression or negative patients.

Cadonilimab was approved by the NMPA in September 2024 for the first-line treatment for advanced gastric cancer, offering a new and effective immunotherapy option. Cadonilimab has been included in the 2025 CSCO Gastric Cancer Guidelines as the only Category I recommendation (Level 1A evidence) for first-line immunotherapy, regardless of PD-L1 expression, and is currently widely used in clinical practice.

Forward-Looking Statement of Akeso, Inc.
This announcement by Akeso, Inc. (9926.HK, “Akeso”) contains “forward-looking statements”. These statements reflect the current beliefs and expectations of Akeso’s management and are subject to significant risks and uncertainties. These statements are not intended to form the basis of any investment decision or any decision to purchase securities of Akeso. There can be no assurance that the drug candidate(s) indicated in this announcement or Akeso’s other pipeline candidates will obtain the required regulatory approvals or achieve commercial success. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in P.R.China, the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Akeso’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Akeso’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

Akeso does not undertake any obligation to publicly revise these forward-looking statements to reflect events or circumstances after the date hereof, except as required by law.

About Akeso
Akeso (HKEX: 9926.HK) is a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of the world’s first or best-in-class innovative biological medicines. Founded in 2012, the company has created a unique integrated R&D innovation system with the comprehensive end-to-end drug development platform (ACE Platform) and bi-specific antibody drug development technology (Tetrabody) as the core, a GMP-compliant manufacturing system and a commercialization system with an advanced operation mode, and has gradually developed into a globally competitive biopharmaceutical company focused on innovative solutions. With fully integrated multi-functional platform, Akeso is internally working on a robust pipeline of over 50 innovative assets in the fields of cancer, autoimmune disease, inflammation, metabolic disease and other major diseases. Among them, 24 candidates have entered clinical trials (including 15 bispecific/multispecific antibodies and bispecific ADCs. Additionally, 7 new drugs are commercially available. Through efficient and breakthrough R&D innovation, Akeso always integrates superior global resources, develops the first-in-class and best-in-class new drugs, provides affordable therapeutic antibodies for patients worldwide, and continuously creates more commercial and social values to become a global leading biopharmaceutical enterprise.

For more information, please visit https://www.akesobio.com/en/about-us/corporate-profile/ and follow us on Linkedin.

• Ivonescimab plus chemotherapy demonstrated a median PFS of 11.14 months, PFS HR=0.60, P < 0.0001.
• The absolute difference in median PFS between the two groups was 4.24 months (ΔPFS = 4.24 months), indicating significantly prolonged progression-free survival with ivonescimab combination therapy.
• Significant benefits were consistently observed with ivonescimab plus chemotherapy versus tislelizumab combination irrespective of PD-L1 expression.
• Ivonescimab combination therapy showed significant benefit over tislelizumab regimen in patients with or without liver metastases and with or without brain metastases.
• In the HARMONi-6 study, 92.3% of enrolled patients had stage IV disease, and approximately 63% had central-type squamous cell carcinoma.
• Ivonescimab demonstrated a favorable overall safety profile with no new safety signals identified.
• Overall survival (OS) data were not yet mature at the time of this analysis.

HONG KONG, Oct. 19, 2025 /PRNewswire/ — Akeso (9926.HK) announced the groundbreaking results of the registrational Phase III clinical study (AK112-306/HARMONi-6) evaluating ivonescimab (PD-1/VEGF bispecific antibody), a globally first-in-class bispecific antibody developed by Akeso, in combination with chemotherapy versus tislelizumab combined with chemotherapy as first-line treatment for advanced squamous non-small cell lung cancer (sq-NSCLC). The study results were presented by Professor Lu Shun, Chief of the Shanghai Lung Cancer Center at Shanghai Chest Hospital and Professor of Medicine at Shanghai Jiaotong University, at the 2025 ESMO Presidential Symposium, and the results of the HARMONi-6 clinical trial were simultaneously published in The Lancet.

The HARMONi-6 study met its primary endpoint of progression-free survival (PFS), demonstrating a decisive and strong positive outcome with both statistically significant and clinically meaningful benefits. Ivonescimab plus chemotherapy substantially prolonged sq-NSCLC patient’s progression-free survival compared to tislelizumab plus chemotherapy:

• The progression-free survival (PFS) hazard ratio (HR) was 0.60 (p < 0.0001) for ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy. The median PFS was 11.14 months in the ivonescimab combination group versus 6.90 months in the tislelizumab combination group, representing an absolute improvement of ΔPFS = 4.24 months.
• Consistent clinical benefits were observed across all PD-L1 expression subgroups. In the PD-L1 negative (TPS <1%) population, the PFS HR was 0.55 for ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy. In the PD-L1 positive (TPS ≥1%) population, the PFS HR was 0.66 for ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy.
• Regardless of liver or brain metastasis, ivonescimab combined with chemotherapy showed significant benefit over the tislelizumab-based regimen. Among patients with liver metastases, the PFS HR was 0.53; among those without liver metastases, the PFS HR was 0.64. For patients with ≥3 baseline metastatic sites, the PFS HR was 0.46, and for those with <3 baseline metastatic sites, the PFS HR was 0.64.

The ivonescimab group demonstrated a favorable overall safety profile with no new safety signals identified. The incidence of treatment-related serious adverse reactions and grade 3 or higher bleeding events was comparable to the tislelizumab regimen group. The most common adverse reactions were chemotherapy-associated myelosuppression.

The HARMONi-6 study enrolled 532 subjects, with balanced baseline characteristics between the two groups. 92.3% of subjects had clinical stage IV disease. The squamous carcinoma characteristics of enrolled patients reflected real-world clinical presentations, with central-type squamous carcinoma accounting for approximately 63% of the total patients (66.9% in the ivonescimab group vs. 59.4% in the tislelizumab group), consistent with real-world patient distribution. PD-L1 expression levels also reflected those seen in real-world clinical settings.

Approved in 2024, ivonescimab has demonstrated groundbreaking clinical value across dozens of clinical studies and real-world treatments involving over 40,000 patients. In the field of tumor immunotherapy, whether compared with PD-1 monotherapy or PD-1 combination chemotherapy (the current standard of care for many cancers), as well as in the field of anti-angiogenesis therapy compared to VEGF-targeted regimens, ivonescimab has demonstrated robust and superior clinical efficacy, highlighting its exceptional capacity to drive iterative advances in cancer treatment.

The encouraging results from the HARMONi-6 study have led to the review of a supplemental New Drug Application (sNDA) in China for ivonescimab in combination with chemotherapy as a first-line treatment for advanced squamous NSCLC. Meanwhile, the global enrollment for the international, multicenter Phase III HARMONi-3 trial, assessing ivonescimab as a first-line treatment for both squamous (sq-NSCLC) and non-squamous (nsq-NSCLC) non-small cell lung cancer is ongoing. 

Forward-Looking Statement of Akeso, Inc.
This announcement by Akeso, Inc. (9926.HK, “Akeso”) contains “forward-looking statements”. These statements reflect the current beliefs and expectations of Akeso’s management and are subject to significant risks and uncertainties. These statements are not intended to form the basis of any investment decision or any decision to purchase securities of Akeso. There can be no assurance that the drug candidate(s) indicated in this announcement or Akeso’s other pipeline candidates will obtain the required regulatory approvals or achieve commercial success. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in P.R.China, the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Akeso’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Akeso’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

Akeso does not undertake any obligation to publicly revise these forward-looking statements to reflect events or circumstances after the date hereof, except as required by law.

About Akeso
Akeso (HKEX: 9926.HK) is a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of the world’s first or best-in-class innovative biological medicines. Founded in 2012, the company has created a unique integrated R&D innovation system with the comprehensive end-to-end drug development platform (ACE Platform) and bi-specific antibody drug development technology (Tetrabody) as the core, a GMP-compliant manufacturing system and a commercialization system with an advanced operation mode, and has gradually developed into a globally competitive biopharmaceutical company focused on innovative solutions. With fully integrated multi-functional platform, Akeso is internally working on a robust pipeline of over 50 innovative assets in the fields of cancer, autoimmune disease, inflammation, metabolic disease and other major diseases. Among them, 24 candidates have entered clinical trials (including 15 bispecific/multispecific antibodies and bispecific ADCs. Additionally, 7 new drugs are commercially available. Through efficient and breakthrough R&D innovation, Akeso always integrates superior global resources, develops the first-in-class and best-in-class new drugs, provides affordable therapeutic antibodies for patients worldwide, and continuously creates more commercial and social values to become a global leading biopharmaceutical enterprise.

For more information, please visit https://www.akesobio.com/en/about-us/corporate-profile/ and follow us on Linkedin.

The company launched American R&D in 2013 and American commercial operations in 2018; in 2020 it opened a 100,000 square foot production and training center in Houston, and just tripled its local footprint to support strong growth.

HOUSTON, Oct. 19, 2025 /PRNewswire/ — United Imaging, a global manufacturer of modern medical imaging technology, saw a record number of visits to its North American hub from U.S. healthcare providers in one week in October, and an overall spike in 2025.

The nearly 100,000 square foot facility first opened its doors in Houston in 2020, and has been welcoming healthcare providers from America and across the globe, both in person and virtually. The facility includes a large technology showroom, production center, training center, service parts distribution warehouse, and corporate offices.

A short five years later, the company has already obtained space in Pearland to triple its production footprint, given strong demand and continued growth in the U.S. market and its first approvals from Health Canada. The expansion was announced in early January.

United Imaging has continuously invested in the American market, bringing multiple new technologies to the U.S. every year to grow its portfolio of medical imaging equipment and offer new capabilities to healthcare providers that can help them expand the services they provide to their communities. They have also innovated a number of service offers and business models that streamline purchases, create investment protection for providers and help keep their equipment modern.

The company globally is present in more than 80 countries, working with hospitals, imaging centers, and academic institutions since 2011. United Imaging’s mission is Equal Healthcare for All.

ABOUT UNITED IMAGING

At United Imaging, we develop and produce advanced medical products, digital healthcare solutions, and intelligent solutions that cover the entire process of imaging diagnosis and treatment. Founded in 2011, our company has subsidiaries and R&D centers across the world. Our North American headquarters in Houston includes our corporate offices, factory, product showroom, service training center, and service parts distribution center. With a cutting-edge digital portfolio and a mission of Equal Healthcare for All™, we help drive industry progress and bold change.